Integrative Molecular Characterization Of MiT Family Translocation Renal Cell Carcinomas (IMCOR)

Study Overview
=================
Brief Summary
-----------------
Microphthalmia transcription factor (MiT) family translocation renal cell carcinomas (TRCC) are rare subtypes of kidney cancers, which often arise in children and young adults. TRCC are characterized by translocations affecting transcription factors: Transcription Factor Binding To Immunoglobulin Heavy Constant Mu Enhancer 3 (TFE3) and Transcription Factor EB (TFEB). Little is known about TRCC molecular heterogeneity, in particular their transcriptomic and epigenetic subtype classification. Clinical behavior of TRCC is varying with age and Tumor, Node, Metastasis (TNM) stage. However, the biological basis of this aggressiveness is poorly understood. PURPOSE: The primary goal of this study is to decipher specific alterations in aggressive TRCC, defined as cases with metastatic dissemination at diagnosis. To tackle this problem, a retrospective cohort of TRCC cases in children and young adults will be created. We will then perform integrative comprehensive multi-omics analysis of these tumors to identify genetic, epigenetic and immune biomarkers associated with metastatic behavior in a training and validation datasets. Comparison of the multi-omics data will be compared to other type of rare Kidney tumors as well as clear-cell renal cell carcinomas

Detailed Description
-----------------
This retrospective cohort study aims to allow tumor collection of TRCC from three different networks: the French research network in renal cancer (UroCCR), the International Society of Paediatric Oncology (SIOP) database and the network for rare renal carcinomas (CARARE). Those samples will be divided in training and validation datasets. We will also collect samples from patients with other rare kidney cancers and clear-cell renal cell carcinomas allowing comparisons of similarity and differences between these tumors.

Official Title
-----------------
Integrative Molecular Characterization Of MiT Family Translocation Renal Cell Carcinomas (IMCOR)

Conditions
-----------------
Renal Carcinoma

Intervention / Treatment
-----------------
* Other: Data collection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients treated for kidney cancer in a clinical center located in France For molecular biology study : Patients with tumor sample available for genetic and epigenetic analysis. Tumor sample stored in Biological resource facilities and consent given from patient or from parents for the use of biological sample for biomedical research purposes. Exclusion Criteria: Objection from patient or parents
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with TRCC<br> | Other: Data collection<br>* Retrospective data collection<br>|
| Patients with other rare kidney tumors<br> | Other: Data collection<br>* Retrospective data collection<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Identification of genetic alterations associated with TRCC aggressiveness. | Tumor aggressiveness is defined as TRCC cases with metastatic dissemination at diagnosis. Comparison of recurrent genetic aberration identified between metastatic and localized cases. | at the end of the study (36 months) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progression free survival (PFS) | Testing for association between molecular tumor features and clinico-pathological patients outcome, PFS, according to the identity of TFE fusion partner | From renal tumor diagnosis to progression or latest patient news at the end of the study (36 months) | 
| Overall survival (OS) | Testing for association between molecular tumor features and clinico-pathological patients outcome, OS, according to the identity of TFE fusion partner | From renal tumor diagnosis to death or latest patient news at the end of the study (36 months)6 months) | 
| Contribution of DNA methylation, transcriptome and immune landscape to metastatic potential | Proportion of patients with metastatic disease in each DNA methylation and messenger RNA (mRNA) cluster using hierarchical unsupervised subtype classifications | at the end of the study (36 months) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
MiT family translocation renal cell carcinomas, Multiomics, Genetic, Epigenetic